Paul Fonteyne's most recent trade in Amylyx Pharmaceuticals Inc was a trade of 24,372 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2026 | 24,372 | 24,372 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 37,500 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | 14 May 2026 | 30,666 | 0 (0%) | 0% | - | Common Stock | ||
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 27,600 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 14,684 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 11,199 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 8,554 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 7,961 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 7,441 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 5,748 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 5,744 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 3,877 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 3,544 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 3,062 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 14,684 | 14,684 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 7,961 | 30,666 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 11,199 | 11,199 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 6,267 | 22,705 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 5,748 | 5,748 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Fonteyne Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 3,341 | 16,438 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 16,985 | 16,985 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 7,441 | 7,441 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 3,867 | 13,097 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 8,400 | 8,400 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Paul Fonteyne | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Jan 2022 | 3,947 | 3,947 | - | 19 | 74,993 | Common Stock |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 8,554 | 8,554 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharma Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 4,230 | 9,230 (0%) | 0% | 0 | Common Stock |